Moderna
-
Can mRNA vaccines do for cancer what they did with Covid-19?
The short answer is that cancer vaccines represent no silver bullet but can prove potent in combination with other immunotherapy and drug cocktails.
-
Moderna’s Covid vaccine shows efficacy in younger teens; regulatory filing are next
Moderna released preliminary clinical data showing its Covid-19 vaccine produced efficacy in adolescents that was comparable to what was seen in adults. The company plans to submit applications to regulators in early June seeking expansion of emergency authorization of the vaccine to include this younger age group.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Moderna’s Covid-19 vaccine gets FDA O.K. for storage changes, extra dose per vial
The FDA increased the maximum number of doses permitted for each vial of Moderna’s Covid-19 vaccine, a change intended to make more doses available. The regulator also authorized storage changes for the vaccines at vaccination sites.
-
Vaccine rollout is an administrative problem, not a distribution issue and is expected to go away
The CEOs of Pfizer, Moderna, McKesson and CVS Health explained that the distribution effort has gone well but the administration of the vaccine has now to catch up. They expect it to happen soon.
-
Moderna CMO at JPM: Our job is complete when we deliver the vaccine
Moderna’s leadership team dodged questions about their assessment of the largely slow and dysfunctional vaccine rollout focusing instead of telling the story of the science behind a decade-old biopharma company whose first commercial product is making history.
-
Covid vaccines appear safe and effective, but key questions remain
The rollout of two newly authorized Covid-19 vaccines is a bright ray of hope at the pandemic’s darkest hour. Both are expected to be available to the public in the first few months of next year. Here are answers to some questions you might be asking yourself about the new vaccines.
-
Moderna, Roche team up to track duration of Covid-19 protection after vaccination
Moderna is using a Roche antibody test in clinical trials of its Covid-19 vaccine. The test can measure the antibodies created through vaccination, offering a window into how long protection lasts.
-
Inside the first chaotic days of the effort to vaccinate America
As Covid-19 vaccine doses make their way around the country, there has been a lack of guidance and miscommunication at the federal level, leaving state officials to make key decisions on distribution amid a chaotic mass vaccination effort.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Precision measurement in 2021: Why accuracy is key to the vaccine ‘cold chain’ and disrupting the spread of Covid-19
By creating new networks for 24/7 temperature monitoring, alerts and reporting, the challenges of deploying transportation at ultra-low temperatures can be overcome. This also illustrates the crucial role that precision measurement will have to play.
-
Pediatricians want kids to be part of Covid vaccine trials
Covid-19’s impact on children represents a tiny fraction of the suffering and death experienced by vulnerable adults. Yet it’s pretty serious having caused 154 deaths and more than 7,500 hospitalizations as of Dec. 3 among people 19 and younger in the United States.
-
FDA panel backs use of Pfizer/BioNTech vaccine for Covid-19
The nonbinding recommendation is a final hurdle before an official emergency use authorization for the vaccine, which could be the first shot approved for use in the U.S. Distribution, however, will remain a challenge.
-
Moderna does one better than Pfizer/BioNTech; touts 94.5% efficacy for its Covid vaccine
The company is the second this month to report promising results for a Covid-19 vaccine even as the virus rages across the U.S.
-
Moderna’s Covid-19 vaccine shows antibody, T-cell responses a month after second dose in interim Phase I data
The company published interim data from the Phase I study of mRNA-1273 in 40 older and elderly adults, showing responses comparable to those seen in younger adults. The vaccine is being tested in a 30,000-participant Phase III trial.
-
Pfizer follows Moderna’s suit in releasing Covid-19 vaccine study protocol
Protocols – essentially the blueprints for clinical trials – are typically kept under wraps until studies are complete, but Pfizer and Moderna have made the ones for their SARS-CoV-2 trials public in a transparency push.